eCite Digital Repository

A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA

Citation

Palmer, AJ and Valentine, WJ and Chen, R and Mehin, N and Gabriel, S and Bregman, B and Rodby, RA, A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA, Nephrology, Dialysis and Transplantation, 23, (4) pp. 1216-1223. ISSN 0931-0509 (2008) [Refereed Article]

DOI: doi:10.1093/ndt/gfn082

Abstract

Background. Nephropathy is an indicator of end-organ damage and is a strong predictor of an increased risk of cardiovascular disease and death in patients with diabetes. Screening can lead to early identification and treatment, both of which incur costs. However, identification and treatment may slow or prevent progression to a more expensive stage of the disease and thus may save money. We assessed the health economic impact of screening for nephropathy (microalbuminuria and overt nephropathy) followed by optimal renoprotective-based antihypertensive therapy in a US setting. Methods. A Markov model simulated the lifetime impact of screening with semi-quantitative urine dipsticks in a primary care setting of hypertensive patients with type 2 diabetes and subsequent treatment with irbesartan 300 mg in patients identified as having nephropathy. Progression from no nephropathy to end-stage renal disease (ESRD) was simulated. Probabilities, utilities, medication and ESRD treatment costs came from published sources. Clinical outcomes and direct medical costs were projected. Second order Monte Carlo simulation was used to account for uncertainty in multiple parameters. Annual discount rates of 3% were used where appropriate. Results. Screening, followed by optimized treatment, led to a 44% reduction in the cumulative incidence of ESRD and improvements in non-discounted life expectancy of 0.25 ± 0.22 years/patient (mean ± SD). Quality-adjusted life expectancy was improved by 0.18 ± 0.15 quality-adjusted life years (QALYs)/patient and direct costs increased by $244 ± 3499/patient. The incremental cost-effectiveness ratio was $20 011 per QALY gained for screening and optimized treatment versus no screening. There was a 77% probability that screening and optimized therapy would be considered cost effective with a willingness to pay a threshold of $50 000. Conclusion. In patients with type 2 diabetes and hypertension, screening for nephropathy and treatment with a renoprotective-based antihypertensive agent was projected to improve patient outcomes and represent excellent value in a US setting. © The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Item Details

Item Type:Refereed Article
Research Division:Economics
Research Group:Applied Economics
Research Field:Health Economics
Objective Division:Health
Objective Group:Health and Support Services
Objective Field:Health Policy Economic Outcomes
Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:74623
Year Published:2008
Web of Science® Times Cited:46
Deposited By:Research Division
Deposited On:2011-12-08
Last Modified:2011-12-13
Downloads:0

Repository Staff Only: item control page